Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | HTT | P42858 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276925 | 0.81 | LMNA (0.48) | LMNAADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL2215019 | 0.79 | NOS3 (0.46) | LMNAADRA2AADRA2BADRA2CGAA | |
| SCHEMBL5970257 | 0.78 | ADRA2A (0.43) | LMNAADRA2AADRA2BADRA2CSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7161081 | 0.75 | ALDH1A1 (0.49) | LMNASMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL601821 | 0.74 | LMNA (0.54) | LMNASMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL3536341 | 0.73 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CSMN1; SMN2GAA | |
| SCHEMBL9045499 | 0.72 | GAA (0.68) | LMNAGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL27853660 | 0.71 | GAA (0.54) | LMNASMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL30858931 | 0.70 | LMNA (0.56) | LMNASMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL134991 | 0.70 | LMNA (0.56) | LMNASMN1; SMN2GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2060569-B1 | Ethyl 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionate methanesulfonate hemihydrate and its use as a medicament | BOEHRINGER INGELHEIM PHARMA (DE) | 2011-10-19 | — | — | EP | claimed |
| EP-0966454-B1 | DISUBSTITUTED BICYCLIC HETEROCYCLES, THEIR PRODUCTION AND USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-05-07 | — | — | EP | claimed |
| EP-1485094-B2 | DOSAGE FORM FOR ORAL ADMINISTRATION OF 3-[(2-{[4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO]-METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)-PYRIDIN-2-YL-AMINO] PROPIONIC ACID ETHYL ESTER OR ITS SALTS | BOEHRINGER INGELHEIM INT (DE) | 2020-03-25 | — | — | EP | disclosed |
| WO-2014020555-A3 | IMPROVED PROCESS FOR PREPARING DABIGATRAN ETEXILATE MESYLATE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014020555-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE MESYLATE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2014-02-06 | — | — | WO | disclosed |
| US-20060183692-A1 | Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy | ASTRAZENECA AB (SE) | 2006-08-17 | — | — | US | disclosed |
| EP-1608311-A1 | USE OF LOW MOLECULAR WEIGHT THROMBIN INHIBITORS IN CHOLESTEROL-LOWERING THERAPY | AstraZeneca AB (SE) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004082702-A1 | USE OF LOW MOLECULAR WEIGHT THROMBIN INHIBITORS IN CHOLESTEROL-LOWERING THERAPY | ASTRAZENECA AB (SE) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183692-A1 | Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy | PCSK9, APOB, PLAT | LMNA 1428/4885ADRA2A 2674/4885ADRA2B 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.